#1 Clinical Trials Search in Europe

Bevacizumab Zirconium Zr-89

This article discusses the use of Bevacizumab Zirconium Zr-89 in clinical trials for patients with Neurofibromatosis Type 2 (NF2). The study aims to validate an imaging biomarker method to predict the effectiveness of bevacizumab treatment in NF2 patients. By using a specialized PET/CT scan with Zr-89 labeled bevacizumab, researchers hope to identify which patients are likely to respond positively to the treatment, potentially avoiding unnecessary side effects and costs for non-responders.

Table of Contents

What is Bevacizumab Zirconium Zr-89?

Bevacizumab Zirconium Zr-89 is an innovative imaging agent being studied for use in patients with Neurofibromatosis Type 2 (NF2). It is a modified version of a drug called bevacizumab (also known as Avastin), which is combined with a radioactive element called Zirconium-89. This combination allows doctors to use special imaging techniques to visualize tumors in NF2 patients[1].

The drug is also referred to as:

  • 89Zr-Bevacizumab
  • Avastin (when referring to the original bevacizumab drug)

Target Condition: Neurofibromatosis Type 2

Neurofibromatosis Type 2 (NF2) is a rare genetic disorder that causes tumors to grow on nerves in the brain and spinal cord. These tumors, while usually non-cancerous, can cause various symptoms including hearing loss, balance problems, and other neurological issues[1].

How Bevacizumab Zirconium Zr-89 Works

Bevacizumab Zirconium Zr-89 is used in combination with a special imaging technique called PET/CT (Positron Emission Tomography/Computed Tomography). Here’s how it works:

  1. Patients receive a small dose (5 mg) of Bevacizumab Zirconium Zr-89 four days before the PET/CT scan[1].
  2. The drug travels through the bloodstream and attaches to the tumors.
  3. During the PET/CT scan, the Zirconium-89 emits signals that can be detected by the scanner, creating detailed images of where the drug has accumulated in the body.
  4. These images help doctors see the tumors and predict how well a patient might respond to treatment with regular bevacizumab.

Clinical Trial Overview

A clinical trial (NCT05685836) is currently studying Bevacizumab Zirconium Zr-89 in NF2 patients. The main goals of this trial are:

  1. To use Bevacizumab Zirconium Zr-89 PET/CT imaging to predict which patients will respond best to bevacizumab treatment[1].
  2. To monitor how well bevacizumab treatment works for NF2 patients over time.

In this trial, patients undergo a Bevacizumab Zirconium Zr-89 PET/CT scan before starting regular bevacizumab treatment. They then receive standard bevacizumab therapy (7.5 mg/kg) every three weeks for six months[1].

Potential Benefits

The use of Bevacizumab Zirconium Zr-89 imaging could potentially offer several benefits:

  • Help predict which patients will respond best to bevacizumab treatment
  • Avoid unnecessary treatment and potential side effects in patients who are unlikely to benefit
  • Reduce financial burden by identifying non-responders early
  • Improve overall treatment outcomes for NF2 patients

Outcome Measures

The clinical trial is measuring several outcomes to assess the effectiveness of the treatment:

  1. Hearing response: This is measured using tests like Word Recognition Score (WRS) and Pure Tone Average (PTA). These tests help determine if there’s any improvement in hearing[1].
  2. Radiographic response: This involves measuring changes in tumor size and characteristics using MRI scans[1].
  3. Vestibular function: Tests like the Video-Head Impulse Test (vHIT) and cervical Vestibular Evoked Myogenic Potential (cVEMP) test are used to assess balance and inner ear function[1].
  4. Quality of life: Patients complete questionnaires about their symptoms and overall quality of life[1].
  5. Physical examination: Doctors perform neurological exams to check for any changes in symptoms or nerve function[1].

Safety Considerations

While the clinical trial is primarily focused on the effectiveness of Bevacizumab Zirconium Zr-89 as an imaging agent, it’s important to note that the safety of patients is also being monitored. This includes:

  • Regular check-ups during the treatment period
  • Monitoring of kidney function through tests like creatinine clearance and estimated glomerular filtration rate (eGFR)[1]
  • Watching for potential side effects of bevacizumab treatment

It’s crucial to remember that Bevacizumab Zirconium Zr-89 is still being studied, and more research is needed to fully understand its benefits and potential risks. Patients should always discuss their treatment options with their healthcare providers.

Aspect Details
Study Type Observational clinical trial
Condition Neurofibromatosis Type 2 (NF2)
Intervention Bevacizumab Zirconium Zr-89 for imaging, followed by standard bevacizumab treatment
Primary Objectives Validate imaging biomarker to predict bevacizumab efficacy
Key Measurements Hearing response, radiographic response, vestibular function, quality of life
Treatment Duration 6 months of bevacizumab therapy
Follow-up Interval Every 3 months

FAQ

  • What is the purpose of using Bevacizumab Zirconium Zr-89 in this clinical trial? Bevacizumab Zirconium Zr-89 is used in this trial as an imaging agent for PET/CT scans. The purpose is to predict which patients with Neurofibromatosis Type 2 (NF2) are likely to respond well to bevacizumab treatment before starting the actual therapy.
  • How is the Bevacizumab Zirconium Zr-89 administered in the study? Patients receive 5 mg of Bevacizumab Zirconium Zr-89 four days before undergoing a PET/CT scan. This is followed by standard bevacizumab therapy, which is given intravenously at a dose of 7.5mg/kg every three weeks for six months.
  • What are the main outcomes being measured in this clinical trial? The main outcomes being measured include hearing response (using Word Recognition Score and Pure Tone Average tests), radiographic response (tumor size changes on MRI, apparent diffusion coefficient, microbleeds, and diffusion restriction), vestibular function, patient-reported outcomes on quality of life, and physical examination results.
  • How long does the treatment and follow-up last in this study? The standard-of-care bevacizumab therapy is administered every three weeks for six months. To monitor the treatment effect, follow-up is performed at 3-month intervals.
  • Who can participate in this clinical trial? This clinical trial is designed for patients with Neurofibromatosis Type 2 (NF2) who are eligible for bevacizumab treatment. Specific eligibility criteria are not provided in the given information, so interested individuals should consult with their healthcare providers or the study coordinators for more details.

Ongoing Clinical Trials on Bevacizumab Zirconium Zr-89

  • Imaging Study with 89Zr-Bevacizumab for Predicting Treatment Effects in Patients with NF2-Related Schwannomatosis

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Neurofibromatosis Type 2 (NF2): A genetic disorder characterized by the growth of noncancerous tumors in the nervous system, particularly affecting the nerves responsible for hearing and balance.
  • Bevacizumab: A medication used to treat various types of cancers and, in this case, to potentially improve nerve functions in NF2 patients. It works by inhibiting the growth of blood vessels that feed tumors.
  • PET/CT scan: A combination of Positron Emission Tomography (PET) and Computed Tomography (CT) scans, used to create detailed, 3D images of the body's structures and functions.
  • Zirconium Zr-89: A radioactive isotope used to label bevacizumab for imaging purposes in this study.
  • Vestibular schwannomas: Benign tumors that develop on the nerve connecting the inner ear to the brain, often associated with NF2.
  • Word Recognition Score (WRS): A hearing test that measures a person's ability to correctly identify and repeat words at a specific volume level.
  • Pure Tone Average (PTA): A hearing test that determines the softest sounds a person can hear at different frequencies, measured in decibels (dB).
  • Apparent Diffusion Coefficient (ADC): A measure used in MRI to quantify the rate of diffusion of water molecules within tissue, which can indicate changes in tumor composition.
  • Video-Head Impulse Test (vHIT): A test used to assess the function of the vestibular system, which is responsible for balance and spatial orientation.
  • Vestibular Evoked Myogenic Potential (VEMP) test: A test that measures the function of certain parts of the inner ear and associated nerves, used to assess balance and hearing.

References